Biomarkers · Chemical
Cardio IQ® Non-HDL and Calculated Components
- LOINC codes
- 13457-7, 17782-4, 1884-6, 2085-9, 2093-3, 2571-8, 30522-7, 43396-1, 43583-4, 43727-7, 43729-3, 47213-4, 54434-6, 86222-7, 86951-1, 9830-1, 33248-6, 64234-8, 79423-0, 8480-6, 95547-6, 95548-4, 95549-2, 2345-7, 4548-4, 95546-8, 1986-9, 89324-8, 92845-7
- Tests that measure Cardio IQ® Non-HDL and Calculated Components
- Quest Diagnostics 8
Ranges
Each lab publishes a reference range for the population groups it tests, usually the middle 95% of results. These intervals describe that population, not an optimal or healthy target. How ranges differ
Quest Diagnostics, Cardio IQ® ASCVD Risk Panel with Score 92052
| Total Cholesterol | Male (mg/dL) | Female (mg/dL) |
|---|---|---|
| <20 Years | <170 | <170 |
| ≥20 Years | <200 | <200 |
| HDL Cholesterol | ||
| <20 Years | >45 | >45 |
| ≥20 Years | ≥40 | ≥50 |
| Triglycerides | ||
| ≤9 Years | <75 | <75 |
| 10-19 Years | <90 | <90 |
| ≥20 Years | <150 | <150 |
| LDL-Cholesterol (Calc) | ||
| <20 Years | <110 | <110 |
| ≥20 Years | <100 | <100 |
| Cholesterol/HDL Ratio (Calc) | <5.0 | <5.0 |
| Non-HDL Cholesterol | ||
| <20 Years | <120 | <120 |
| ≥20 Years | <130 | <130 |
| <130, ASCVD Risk Scores | See Laboratory Report |
Quest Diagnostics, Lipid Panel, Cardio IQ® 91716
| Total Cholesterol | Male (mg/dL) | Female (mg/dL) |
|---|---|---|
| <20 Years | <170 | <170 |
| ≥20 Years | <200 | <200 |
| HDL Cholesterol | ||
| <20 Years | >45 | >45 |
| ≥20 Years | ≥40 | ≥50 |
| Triglycerides | ||
| ≤9 Years | <75 | <75 |
| 10-19 Years | <90 | <90 |
| ≥20 Years | <150 | <150 |
| LDL-Cholesterol | Not stated | |
| Non-HDL Cholesterol | Not stated | |
| <150, <20 Years | <110 mg/dL (calc) | |
| <150, ≥20 Years | <100 mg/dL (calc) | |
| <150, Cholesterol/HDL Ratio | <5.0 calc | |
| <150, <20 Years | <120 mg/dL (calc) | |
| <150, ≥20 Years | <130 mg/dL (calc) |
Tests
Check the catalog code, specimen, method and preparation for every test that measures Cardio IQ® Non-HDL and Calculated Components. Select up to five tests to compare them side by side.
Quest Diagnostics 8 tests
Panels that include this biomarker
Lipid Panel with Reflex to Direct LDL, Cardio IQ® 92061
4 analytes · Serum · Fasting not stated
Quest Diagnostics catalog pageMethod and collection
- Method
- See individual tests
- Preparation
- If a cholesterol measurement is to be performed along with triglycerides, but not part of a lipid panel, then the patient should be fasting 9-12 hours prior to collection. If the cholesterol is ordered as part of a lipid panel, then a fasting sample is not required. The assay manufacturer Beckman Coulter advises: N-Acetyl Cysteine (NAC), when administered in therapeutic concentrations (for the treatment of acetaminophen overdose), has been determined to interfere with assays for cholesterol and uric acid where "NAC interference may lead to falsely low results." According to Beckman Coulter, the NAC interference should be insignificant by 12 hours after completion of the initial loading dose of an IV infusion treatment regimen consisting of an initial loading dose of 150 mg/kg administered over 1 hour, a second dose of 50 mg/kg administered over 4 hours and a third dose of 100 mg/kg administered over 16 hours.
- Collection
- Only serum is acceptable
- Reference notes
- See individual tests
Cardio IQ® Diabetes and ASCVD Risk Panel with Scores 92063
7 analytes · Serum · Fasting not stated
Quest Diagnostics catalog pageMethod and collection
- Method
- Turbidimetric Inhibition Immunoassay • Spectrophotometry (SP)
- Preparation
- If a cholesterol measurement is to be performed along with triglycerides, but not part of a lipid panel, then the patient should be fasting 9-12 hours prior to collection. If the cholesterol is ordered as part of a lipid panel, then a fasting sample is not required. The assay manufacturer Beckman Coulter advises: N-Acetyl Cysteine (NAC), when administered in therapeutic concentrations (for the treatment of acetaminophen overdose), has been determined to interfere with assays for cholesterol and uric acid where "NAC interference may lead to falsely low results." According to Beckman Coulter, the NAC interference should be insignificant by 12 hours after completion of the initial loading dose of an IV infusion treatment regimen consisting of an initial loading dose of 150 mg/kg administered over 1 hour, a second dose of 50 mg/kg administered over 4 hours and a third dose of 100 mg/kg administered over 16 hours.
- Collection
- For risk calculations to be performed, the following patient-specific information must be provided at the time of order: Age: Years Gender: M (for male) or F (for female) Race - African American: Y (for yes) or N (for no) Systolic Blood Pressure: mmHg Treatment for High B.P.: Y (for yes) or N (for no) Diabetes Status: Y (for yes) or N (for no) Smoking Status: Y (for yes) or N (for no)
- Reference notes
- See individual tests For additional information, please refer to: http://education.QuestDiagnostics.com/faq/FAQ142 (This link is being provided for informational/educational purposes only.)
Cardio IQ® Diabetes Risk Panel with Score 92026
7 analytes · Serum · Fasting not stated
Quest Diagnostics catalog pageMethod and collection
- Method
- Turbidimetric Inhibition Immunoassay • Spectrophotometry (SP)
- Preparation
- If a cholesterol measurement is to be performed along with triglycerides, but not part of a lipid panel, then the patient should be fasting 9-12 hours prior to collection. If the cholesterol is ordered as part of a lipid panel, then a fasting sample is not required. The assay manufacturer Beckman Coulter advises: N-Acetyl Cysteine (NAC), when administered in therapeutic concentrations (for the treatment of acetaminophen overdose), has been determined to interfere with assays for cholesterol and uric acid where "NAC interference may lead to falsely low results." According to Beckman Coulter, the NAC interference should be insignificant by 12 hours after completion of the initial loading dose of an IV infusion treatment regimen consisting of an initial loading dose of 150 mg/kg administered over 1 hour, a second dose of 50 mg/kg administered over 4 hours and a third dose of 100 mg/kg administered over 16 hours.
- Collection
- For risk calculations to be performed, the following patient-specific information must be provided at the time of order: Age: Years Gender: M (for male) or F (for female)
- Reference notes
- See individual tests
Lipid Panel, Cardio IQ® 91716
7 analytes · Serum · Fasting not stated
Quest Diagnostics catalog pageMethod and collection
- Method
- Spectrophotometry (SP)
- Preparation
- If a cholesterol measurement is to be performed along with triglycerides, but not part of a lipid panel, then the patient should be fasting 9-12 hours prior to collection. If the cholesterol is ordered as part of a lipid panel, then a fasting sample is not required. The assay manufacturer Beckman Coulter advises: N-Acetyl Cysteine (NAC), when administered in therapeutic concentrations (for the treatment of acetaminophen overdose), has been determined to interfere with assays for cholesterol and uric acid where "NAC interference may lead to falsely low results." According to Beckman Coulter, the NAC interference should be insignificant by 12 hours after completion of the initial loading dose of an IV infusion treatment regimen consisting of an initial loading dose of 150 mg/kg administered over 1 hour, a second dose of 50 mg/kg administered over 4 hours and a third dose of 100 mg/kg administered over 16 hours.
Advanced Lipid Panel, Cardio IQ® 92145
8 analytes · Serum · Fasting not stated
Quest Diagnostics catalog pageMethod and collection
- Method
- Enzymatic • Nephelometry • Immunoturbidometric • Ion Mobility • Spectrophotometry (SP)
- Preparation
- If a cholesterol measurement is to be performed along with triglycerides, but not part of a lipid panel, then the patient should be fasting 9-12 hours prior to collection. If the cholesterol is ordered as part of a lipid panel, then a fasting sample is not required. The assay manufacturer Beckman Coulter advises: N-Acetyl Cysteine (NAC), when administered in therapeutic concentrations (for the treatment of acetaminophen overdose), has been determined to interfere with assays for cholesterol and uric acid where "NAC interference may lead to falsely low results." According to Beckman Coulter, the NAC interference should be insignificant by 12 hours after completion of the initial loading dose of an IV infusion treatment regimen consisting of an initial loading dose of 150 mg/kg administered over 1 hour, a second dose of 50 mg/kg administered over 4 hours and a third dose of 100 mg/kg administered over 16 hours.
- Reference notes
- See Laboratory Report
0 of 5 tests selected
Pick one moreSources
Quest Diagnostics test catalog
8 tests: codes, specimens, methods, preparation and reference intervals.
LOINC 13457-7, 17782-4, 1884-6, 2085-9, 2093-3, 2571-8, 30522-7, 43396-1, 43583-4, 43727-7, 43729-3, 47213-4, 54434-6, 86222-7, 86951-1, 9830-1, 33248-6, 64234-8, 79423-0, 8480-6, 95547-6, 95548-4, 95549-2, 2345-7, 4548-4, 95546-8, 1986-9, 89324-8, 92845-7
Regenstrief Institute codes that identify the same result across labs.
Search ClinicalTrials.gov for Cardio IQ® Non-HDL and Calculated Components
Registered studies that measure Cardio IQ® Non-HDL and Calculated Components, on the U.S. National Library of Medicine registry.
Verify these ranges and sources
We compile this page from named laboratory catalogs, guidelines and studies. Labs calculate reference intervals from the people they test, for one assay method and one population group, so an interval describes that population rather than an optimal target.
Interpret your own results with a licensed clinician, or track your lab history and health goals in Aumnivida.
Spotted an error? Email hello@biomarkerlens.com with the page URL and the primary source that corrects the entry.